Phosphoinositide 3-kinase catalytic subunit beta (PI3K p110β)

Phosphoinositide 3-kinase catalytic subunit beta (PI3K p110β) is one of the three class IA catalytic subunits of PI3K, encoded by the PIK3CB gene and ubiquitously expressed in mammalian tissues[4][6]. As a lipid kinase, p110β partners with regulatory subunits (notably p85) to catalyze the phosphorylation of phosphatidylinositol (4,5)-bisphosphate, generating PIP3 and initiating intracellular signaling cascades primarily involved in cell growth, survival, metabolism, and cytoskeletal rearrangement[2][4]. p110β is uniquely responsive to signals from G protein-coupled receptors as well as receptor tyrosine kinases and is especially important for maintaining PI3K signaling in cells lacking PTEN, a key tumor suppressor[3]. Aberrations in p110β signaling have been linked to cancer (notably PTEN-deficient tumors), metabolic diseases, and thrombosis, making it a target of interest for anticancer and antithrombotic drug development[2][3]. Selective pharmacological inhibitors of p110β are under investigation, but clinical development must balance efficacy against potential disruption of normal metabolic and hematological functions[2][3].

Other names

PI3K betaPI3K p110 betaPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformPIK3CB (gene symbol)p110β

Inhibition leads to blockade of PI3K/Akt signaling pathway, decreasing downstream survival and growth signals[3]. Antithrombotic action by reducing platelet aggregation[3]. Potential antiproliferative effects in PTEN-deficient tumor cells[3].